Skip to content

Liquidia Corporation LQDA Cash & Equivalents

Cash & Equivalents at other companies

Tenet Healthcare logo
Tenet HealthcareTHC
$2.97B-1.1%
United Therapeutics logo
United TherapeuticsUTHR
$1.28B-32.6%
Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM

Other financials

Income statement

See full
Revenue$132.9M+4,158%
Gross profit$1.6M+6.5%
Operating income$61.5M+274%
Net income$52.9M+238%
EPS (diluted)$0.52+216%

Balance sheet

See full
Total debt$7.0M+1.5%
Total equity$108.6M+118%
Total assets$401.5M+76.6%

Cash flow

See full
Operating cash flow$53.0M+273%
CapEx$2.8M+758%
Free cash flow$50.2M+262%

Valuation

See full
Market cap$6.32B+164%
Enterprise value$6.1B+184%
P/S21.9×-147×

Profitability

See full
Gross margin58.1%-18.7pp
Operating margin-155%-68.1pp
Net margin-176.2%-76.4pp
FCF margin-150.7%-64.4pp

Returns & leverage

See full
Return on equity-181%+57.4pp
Debt / equity0.1×-0.1×
Current ratio2.2×-0.7×

Where this comes from

Reported directly by Liquidia Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Liquidia Corporation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Liquidia Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Liquidia Corporation's cash & equivalents?
Liquidia Corporation (LQDA) reported cash & equivalents of $222.79M in Q1 2026.
How has Liquidia Corporation's cash & equivalents changed year-over-year?
Liquidia Corporation's cash & equivalents increased by 31.2% year-over-year, from $169.76M to $222.79M.
What is the long-term trend for Liquidia Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Liquidia Corporation's cash & equivalents has grown at a 23.9% compound annual growth rate (CAGR), from $65.32M to $190.68M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.